Development of a Disease Model for Predicting Postoperative Delirium Using Combined Blood Biomarkers.

Abstract

Objective: Postoperative delirium, a common neurocognitive complication after surgery and anesthesia, requires early detection for potential intervention. Herein, we constructed a multidimensional postoperative delirium risk-prediction model incorporating multiple demographic parameters and blood biomarkers to enhance prediction accuracy.

Methods: We included 555 patients undergoing radical surgery for colorectal cancer. Demographic characteristics and lipid profiles were collected preoperatively, and perioperative anesthesia and surgical conditions were recorded; blood biomarkers were measured before and after surgery. The 3D-CAM scale was used to assess postoperative delirium occurrence within 3 days after surgery. Patients were divided into the postoperative delirium (N = 100) and non-postoperative delirium (N = 455) groups. Based on machine learning, linear and nine non-linear models were developed and compared to select the optimal model. Shapley value-interpretation methods and mediation analysis were used to assess feature importance and interaction.

Results: The median age of the participants was 65 years (interquartile range: 56-71 years; 57.8% male). Among the 10 machine-learning models, the random forest model performed the best (validation cohort, area under the receiver operating characteristic curve of 0.795 [0.704-0.885]). Lipid profile (total cholesterol, triglycerides, and trimethylamine-N-oxide) levels were identified as key postoperative delirium predictors. Mediation analysis further confirmed mediating effects among total cholesterol, trimethylamine-N-oxide, and postoperative delirium; a nomogram model was developed as a web-based tool for external validation and use by other clinicians.

Interpretation: Blood biomarkers are crucial in predicting postoperative delirium and aid anesthesiologists in identifying its risks in a timely manner. This model facilitates personalized perioperative management and reduces the occurrence of postoperative delirium.

Trial registration: ChiCTR2300075723.